Your English writing platform
Discover LudwigSuggestions(4)
Exact(8)
Both agents demonstrate marked interpatient variability in drug clearance, similar to docetaxel.
[BG] decreased modestly for 50 minutes, after which there was marked interpatient variability in subsequent [BG] trend.
There was marked interpatient variability in topoisomerase II α levels measured from peripheral lymphocytes, with no observed increase following topotecan.
However, nevirapine pharmacokinetics exhibit marked interpatient variability that can be explained in part by genetic differences, drug-drug interactions, pregnancy and other (ethnic) factors [ 10– 10].
A small phase II trial of atRA in patients with hormone refractory metastatic breast cancer showed it to be relatively well tolerated, but noted only one partial response among 14 evaluable patients - although there was marked interpatient variability in pharmacokinetics [ 71].
Marked interpatient variability was found in 22 patients in the pharmacokinetic data, apparently not associated with the drug concentration in the plasma.
Similar(52)
Despite its prevalence and rising incidence, NAFLD is marked by substantial interpatient variability in prognosis and continues to lack the breadth of therapeutic research and development shared by other causes of chronic liver disease.
Interpatient variability in Vss and t½z values was marked, but overall mean values were similar to those described for single-agent docetaxel (Vss=93 versus 67 l m−2; t½z=12 versus 11 h).
In addition, reduced interpatient variability of glucose levels also merits notice.
Interpatient variability in efavirenz concentrations may be due to CYP2B6 genetic polymorphisms.
This helps us to understand and address the effect of interpatient variability on protocol design.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com